Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Novavax has announced that its COVID-19 vaccine NVX-CoV2373 has a final efficacy of 96.
YouTube removed 30,000 videos with vaccine misinformation
YouTube removed 30,000 videos with vaccine misinformation
YouTube has taken down more than 30,000 videos containing misinformation about the coronavirus vaccine since October, a company spokesperson told The Hill Thursday.
Researchers boost potency of an HIV-1 antibody, tracing new pathways for vaccine development
Researchers boost potency of an HIV-1 antibody, tracing new pathways for vaccine development
Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.
AI Helps Identify Possible Alzheimer’s Treatments
AI Helps Identify Possible Alzheimer’s Treatments
Researchers at Massachusetts General Hospital developed an artificial intelligence (AI) that quickly identifies drugs currently available that might treat Alzheimer’s disease.
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
The phase IIa proof-of-concept findings from ViiV Healthcare’s innovative early pipeline of medicines show the antiviral activity, safety and tolerability of GSK’254 and support its continued stud...
Second shot of COVID-19 vaccine may not be necessary in previously infected individuals: study
Second shot of COVID-19 vaccine may not be necessary in previously infected individuals: study
A single shot of one of the currently authorized COVID-19 vaccines may be sufficient to provide immunity to individuals who have previously been infected by the virus, thus eliminating the need for a ...
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
BOSTON, MA, USA I March 10, 2021 IVertex Pharmaceuticals Incorporated (Nasdaq.
Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Novartis has announced that its interleukin-1beta (IL-1β) inhibitor canakinumab failed to hit the primary endpoint of overall survival in a Phase III non-small cell lung cancer (NSCLC)...
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
CAMBRIDGE, Mass.
Roche withdraws US indication for Tecentriq in bladder cancer
Roche withdraws US indication for Tecentriq in bladder cancer
Swiss pharma company Roche has announced that it will withdraw the US indication for Tecentriq in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer).
Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study
Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study
NEW YORK (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study p...
Lupin launches generic diarrhea drug in US market
Lupin launches generic diarrhea drug in US market
Drug major Lupin on Wednesday said it has launched Nitazoxanide tablets (500 mg), used to treat diarrhea, in the US market.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand